共 50 条
Dose Effect of Dual Delivery of Vascular Endothelial Growth Factor and Bone Morphogenetic Protein-2 on Bone Regeneration in a Rat Critical-Size Defect Model
被引:211
|作者:
Young, Simon
[1
]
Patel, Zarana S.
[1
]
Kretlow, James D.
[1
]
Murphy, Matthew B.
[1
]
Mountziaris, Paschalia M.
[1
]
Baggett, L. Scott
[2
]
Ueda, Hiroki
[3
]
Tabata, Yasuhiko
[4
]
Jansen, John A.
[5
]
Wong, Mark
[6
]
Mikos, Antonios G.
[1
]
机构:
[1] Rice Univ, Dept Bioengn, Houston, TX 77251 USA
[2] Rice Univ, Dept Stat, Houston, TX 77251 USA
[3] Hyogo Univ Hlth Sci, Sch Pharm, Chuo Ku, Kobe, Hyogo, Japan
[4] Kyoto Univ, Dept Biomat, Field Tissue Engn, Inst Frontier Med Sci,Sakyo Ku, Kyoto, Japan
[5] Radboud Univ Nijmegen, Med Ctr, Dept Periodontol & Biomat, NL-6525 ED Nijmegen, Netherlands
[6] Univ Texas Hlth Sci Ctr Houston, Dept Oral & Maxillofacial Surg, Houston, TX USA
关键词:
GLYCOL) FUMARATE) HYDROGELS;
TOOTH EXTRACTION SOCKETS;
THROMBIN-RELATED PEPTIDE;
MESENCHYMAL STEM-CELLS;
IN-VITRO;
TRANSFORMING GROWTH-FACTOR-BETA-1;
GELATIN MICROPARTICLES;
CONTROLLED-RELEASE;
TEMPORAL LOCALIZATION;
RABBIT MODEL;
D O I:
10.1089/ten.tea.2008.0510
中图分类号:
Q813 [细胞工程];
学科分类号:
摘要:
The dose effect of dual delivery of vascular endothelial growth factor (VEGF) and bone morphogenetic protein-2 (BMP-2) on bone regeneration was investigated in a rat cranial critical-size defect (CSD). It was hypothesized that decreasing amounts of BMP-2 would result in a dose-dependent decrease in bone formation, and that this reduction in bone formation could be reversed by adding increasing amounts of VEGF. In vitro release kinetics of VEGF or BMP-2 were examined over 28 days. Next, scaffolds were implanted within a rat cranial CSD containing different combinations of both BMP-2 and VEGF. At 12 weeks, samples were analyzed using microcomputed tomography and histology. In vitro, VEGF and BMP-2 exhibited burst release in the first 24 h followed by a significant decrease in release rate over 27 days. Overall, BMP-2 had a more sustained release versus VEGF. An in vivo dose-dependent decrease in percentage of bone fill (PBF) was observed for BMP-2. The addition of VEGF was unable to reverse this decrease in PBF, although improvements in the number of bridged defects did occur in some groups. This suggests that for this particular model simultaneous release of BMP-2 and VEGF does not increase bone formation over BMP-2 alone at 12 weeks.
引用
收藏
页码:2347 / 2362
页数:16
相关论文